• Explore /
  • Poster
  • / Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Abstract Poster

Authors

Maria Catherine Pietanza

Maria Catherine Pietanza

Memorial Sloan Kettering Cancer Center, New York, NY

Maria Catherine Pietanza , Alexander I. Spira , Robert M. Jotte , Shirish M. Gadgeel , Alain C. Mita , Lowell L. Hart , W Larry Gluck , Anne C. Chiang , Stephen V. Liu , Ann M. Kapoun , Lu Xu , Dawn Hill , Jakob Dupont , David R. Spigel , Lei Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01859741

Citation

J Clin Oncol 33, 2015 (suppl; abstr 7508)

DOI

10.1200/jco.2015.33.15_suppl.7508

Abstract #

7508

Poster Bd #

255

Abstract Disclosures

Similar Posters

First Author: Anne C. Chiang

First Author: Joachim Von Pawel

Poster

2013 ASCO Annual Meeting

Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop).

Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop).

First Author: Sanjeeve Balasubramaniam

First Author: A. M. Traynor